BiotechTube
Synergy Biomedical

Synergy Biomedical

Malvern, United States· Est.
synergybiomedical.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $10M

Overview

Synergy Biomedical is a commercial-stage medical device company focused on advancing bone healing through its proprietary bioactive glass technology. The company's BioSphere® product portfolio, including putties and delivery systems, is designed as a synthetic alternative to autografts and allografts, targeting the orthopedic bone graft substitute market. Led by an experienced management team with deep orthopedic industry backgrounds, Synergy has successfully launched multiple products and appears to be in a revenue-generating phase. Its strategy centers on product line extensions and leveraging the unique material properties of its engineered spherical bioactive glass particles.

OrthopedicsSpineExtremities

Technology Platform

Proprietary 45S5 bioactive glass engineered into spherical particles with a bimodal size distribution to optimize osteoconduction, handling, and bone healing performance for synthetic bone graft substitutes.

Funding History

2
Total raised:$10M
Seed$8M
Grant$2M

Opportunities

The growing global bone graft substitute market, driven by an aging population and a shift away from autografts, presents a significant opportunity.
Targeted expansion into high-growth segments like extremities surgery and minimally invasive spine procedures allows for focused commercial penetration.
The purely synthetic and engineered nature of its bioactive glass offers a differentiated value proposition against traditional allografts and other synthetic materials.

Risk Factors

The company faces intense competition from large, well-capitalized orthopedic corporations with broader portfolios.
Its business is highly dependent on the clinical and commercial success of its single bioactive glass technology platform.
As a smaller private company, it also carries execution risks in sales growth, supply chain management, and competing for surgeon adoption.

Competitive Landscape

Synergy operates in the highly competitive synthetic bone graft substitute market, competing directly with major orthopedic players like Stryker (Vitoss), Medtronic, and Zimmer Biomet, as well as other specialized biomaterial companies. Its key differentiator is the specific engineering of its spherical, bimodal bioactive glass particles, which it positions as superior in handling and bone healing performance compared to other synthetic granules, putties, and demineralized bone matrices (DBM).

More companies in Regenerative Medicine →More companies in United States →